Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBT Margin (2016 - 2025)

Historic EBT Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 207.53%.

  • Voyager Therapeutics' EBT Margin fell 1709800.0% to 207.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 401.76%, marking a year-over-year decrease of 4181100.0%. This contributed to the annual value of 80.42% for FY2024, which is 1339100.0% down from last year.
  • Voyager Therapeutics' EBT Margin amounted to 207.53% in Q3 2025, which was down 1709800.0% from 641.67% recorded in Q2 2025.
  • Voyager Therapeutics' EBT Margin's 5-year high stood at 1523.23% during Q4 2022, with a 5-year trough of 3239.97% in Q1 2022.
  • Its 5-year average for EBT Margin is 599.31%, with a median of 393.32% in 2021.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -28466500bps in 2022, then skyrocketed by 33228700bps in 2023.
  • Over the past 5 years, Voyager Therapeutics' EBT Margin (Quarter) stood at 18.02% in 2021, then surged by 8353bps to 1523.23% in 2022, then plummeted by -96bps to 63.53% in 2023, then tumbled by -950bps to 540.03% in 2024, then skyrocketed by 62bps to 207.53% in 2025.
  • Its last three reported values are 207.53% in Q3 2025, 641.67% for Q2 2025, and 476.68% during Q1 2025.